Article Text

Download PDFPDF
Epithelial ingrowth cells after LASIK/ALTK (automated lamellar therapeutic keratoplasty): are they corneal epithelial stem cells?
  1. Michael Nicolas1,
  2. Hana Abouzeid1,
  3. Manuel Deprez1,2,
  4. Farhad Hafezi3,
  5. Francis L Munier1,
  6. Zsolt Varga4,
  7. François Majo1
  1. 1Jules-Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland
  2. 2Laboratory of Neuropathology, Centre Hospitalier Universitaire, University of Liège, Liège, Belgium
  3. 3Division of Ophthalmology, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland
  4. 4Leeds Teaching Hospitals NHS Trust, Leeds, UK
  1. Correspondence to Dr François Majo, Jules-Gonin Eye Hospital, 15 Avenue de France, 1004 Lausanne, Switzerland; fmajo{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Epithelial ingrowth (EI) is a severe and incompletely understood complication after laser-assisted in situ keratomileusis (LASIK). Its incidence is variable and cases requiring surgical removal occur with a frequency of 0.92%–2.2%.1 ,2 Here, we report the clinical, morphological and immunohistological features of EI cells of four patients, two LASIKs, one FemtoLASIK and one ALTK, with EI that needed surgical removal (figure 1A). Immunohistochemistry was performed using antibodies against CK3, Muc5AC, CK15 and CK19 (differentiation markers) and against p63, BMI1, C/EBP δ and BCRP/ABCG2 (stem cell markers) and Ki67 (proliferation marker).3

Figure 1

Slit lamp images of the patients, histopathology and immunostaining of epithelial ingrowth (EI) specimens. (A) Case 1 underwent a Femtolaser-assisted in situ keratomileusis (FemtoLASIK) procedure for hyperopia, cases 2 and 4 a LASIK for myopia and hyperopia, respectively, and case 3 had an automated lamellar therapeutic …

View Full Text


  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Authorisation # 035.0003-48.

  • Provenance and peer review Not commissioned; externally peer reviewed.